Aldeyra Therapeutics, Inc.
Quick facts
Phase 3 pipeline
- ICM ADX-2191 injection · Immunology
ADX-2191 is a reactive aldehyde species that inhibits aldehyde dehydrogenase (ALDH) to modulate immune and inflammatory responses. - Monthly ADX-2191 injection · Ophthalmology
ADX-2191 is a reactive aldehyde species (RAS) scavenger that binds and neutralizes pathogenic aldehydes implicated in ocular surface inflammation and disease. - Vehicle of ADX-102 Ophthalmic Drops · Ophthalmology
This is a vehicle formulation (inactive carrier system) for ADX-102, designed to deliver the active pharmaceutical ingredient to the ocular surface. - Vehicle of ADX-102 Topical Dermal Cream · Ophthalmology, Dermatology
ADX-102 is a topical dermal cream that targets the complement pathway to reduce inflammation. - Vehicle Ophthalmic Solution QID · Ophthalmology
Vehicle Ophthalmic Solution QID is a carrier solution used in clinical trials to deliver active drugs to the eye, without having a direct therapeutic effect itself. - Vehicle Ophthalmic Solution QID to BID · Ophthalmology
A vehicle ophthalmic solution formulation designed to be administered topically to the eye at varying frequencies (four times daily reduced to twice daily). - Vehicle Opthalmic Solution · Ophthalmology
Vehicle Ophthalmic Solution is a non-medicated solution used to flush out the eye.
Phase 2 pipeline
- Active topical NS2 1% dermatologic cream · Dermatology
Active topical NS2 1% dermatologic cream works by targeting the underlying cause of inflammation in the skin. - ADX-2191 · Ophthalmology
ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation. - ADX-629
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: